News & Views
Partership Extend Capability for Virus Inactivation
Nov 13 2008
developed to inactivate viruses in biopharmaceuticals by UVC irradiation. Typically used for virus inactivation of cell culture media, antibody solutions and irradiation of vaccines and therapeutics produced from blood and plasma,further areas of application, such as
removal of mycoplasma from bioreactor media, are currently being assessed.
Regulations concerning viral safety in biopharmaceutical manufacturing processes already require manufacturers to provide at least two complementary technologies for virus clearance, during early clinical phases.
This partnership now adds a third method to Sartorius Stedim Biotech`s portfolio, creating what has been described as an âorthogonal technology platformâ for broad spectrum virus removal through
nanofiltration, adsorption and now UVC irradiation products.
The technology is scalable and will be marketed as single-use modules, laboratory bench units and process systems with joint collaboration on further process development and engineering services, as well as
advancement of the technology.
Following the partnership agreement, Sartorius Stedim Biotech has signed a purchase contract with the Belgian Red Cross on patents to use UVC technology for blood fractionation and manufacture of biotech
products.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark